- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02529683
Study of Nuvaring Acceptability, Adherence and Biological Effects Among HIV-negative Women in Kenya
Clinical Trial of Acceptability, Adherence and Immune/Microbiologic Effects of a Vaginal Contraceptive Ring Among HIV-negative Women in Western Kenya
Study Overview
Detailed Description
Background: Adherence to HIV prevention and contraception technologies is imperfect but a key to effectiveness. The options currently available to protect women from HIV infection and unwanted pregnancy (e. g. condom use, abstinence, monogamy) are not consistently available, practical, or under women's control. Intravaginal rings (IVRs) are an important technology that can be long-acting and woman-controlled and are being developed for HIV prevention with and without co-formulated hormonal contraception. Availability of IVRs in sub-Saharan Africa is limited; hence, it is important to evaluate acceptability, utilization, and biologic effects of IVR usage among African women. The NuvaRing® intravaginal combined hormonal contraceptive ring is used successfully in 61 countries worldwide, although not currently in Kenya. NuvaRing is self-inserted for 21 days starting after the last day of menses then removed for seven days to allow menses to occur, and has comparable effectiveness to oral contraceptives. Adherence to HIV prevention and contraception technologies like the IVR is critical to optimizing effectiveness. In preparation for a potential future Phase 2 trial of a combination antiretroviral-contraceptive IVR, KEMRI/CDC proposes to examine adherence, acceptability and biological effects of NuvaRing® among Kenyan women already using a modern method of contraception.
Objectives:
- To assess adherence and utilization patterns for NuvaRing®, behaviourally and biologically.
- To assess acceptability and effect of NuvaRing® on sexual behaviour among women and their sexual partners in a setting where there is no routine IVR use. At the end of the NuvaRing® trial, to additionally assess the hypothetical acceptability of a prototype dual use HIV-prevention and contraceptive IVR among women who had used NuvaRing® and among women who have never used an IVR.
- To assess biologic effects of NuvaRing® including standard safety monitoring and, among a subset of participants, genital compartment immunology and microbiology.
Study Subjects: A total of 220 women and 20 men will be enrolled in different parts of the proposed study. The primary NuvaRing® trial participants (Objectives 1 and 2 above) will be up to 200 young, healthy women recruited from family planning clinics in the Kisumu catchment area. Fifty of these women will form a biomedical subgroup addressing Objective 3. To augment Objective 2, twenty trial participants and their sexual partners will take part in a qualitative in-depth interview, and three focus group discussions will be conducted, one with study participants and the others with 20 women who were not part of the primary NuvaRing® trial.
Design: Single arm clinical trial with up to 3 month pre-product phase (on oral or injectable contraceptives) followed by 6 months of IVR use, ending with an up to 3 month post-product phase during which women return to oral or injectable contraceptives and then exit the study. Monthly and quarterly follow-up will include adherence, acceptability and clinical assessments, and HIV and pregnancy testing. Women in the biomedical subgroup will undergo more frequent visits and collection of genital specimens. In-depth interview and focus group discussions are delineated under 'Study Subjects' above.
Outcome: The study will improve understanding of adherence to biomedical technologies, facilitate the conduct of future HIV microbicide clinical trials relying on IVR technology, and inform public health practice regarding contraception.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 to 34 years of age - Age will be verified using a standard national document e.g. Identity card, birth notification etc., and in case they are missing we will rely on proxy verification. Everyone in Kenya over the age of 18 is required to have a government-issued identification card, which includes their date of birth. There is some likelihood that women who are interested do not have this card and do not know their year of birth. In such, instances the participant will be asked her age and birth month. The day of birth will be defaulted to the 15th and year of birth will be calculated using the available information if not provided by the participant. In instances, where age cannot be verified, participation will not be permitted.
- Fluent in English, Swahili, or DhoLuo
- Resident of the Kisumu catchment area (≈150 kilometres from Kisumu City)
- Able and willing to provide written informed consent
- Willing to provide detailed locator information and not planning to relocate outside the study area for next 12 months
- Engaged in more than one episode of vaginal intercourse on different days in the past 30 days
- Female, not currently pregnant and not intending to get pregnant for the next 12 months
Demonstrated willingness to prevent conception for the next 12 months, based on:
o Documented receipt of three on-time monthly oral contraceptive pill (OCP) refills, or one DMPA injection at a FP clinic in the last 3 months prior to enrolling in the study.
- Willing to exclusively use IVR for contraception for the duration of the intervention phase of study. (Proper and consistent condom use will be encouraged and condoms will be provided for STI/HIV prevention)
- HIV negative per Kenya's HIV testing algorithm (using rapid tests)
- Willing to undergo periodic study procedures including pregnancy testing, HIV and STI testing
Exclusion Criteria:
Participants will be excluded from the study based on:
- Known medical contraindications:
- Thrombophlebitis or thromboembolic disorders (current or history)
- Cerebral vascular or coronary artery disease (current or history)
- Valvular heart disease with thrombogenic complications
- Severe hypertension
- Diabetes with vascular involvement
- Headaches with focal neurological symptoms
- Major surgery with prolonged immobilization
- Known or suspected carcinoma of the breast or personal history of breast cancer
- Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia
- Undiagnosed abnormal genital bleeding
- Cholestatic jaundice of pregnancy or jaundice with prior hormonal contraceptive use
- Hepatic tumours (benign or malignant) or active liver disease
- Known or suspected pregnancy
- Heavy smoking (≥15 cigarettes per day) and over age 35
- Hypersensitivity to any of the components of NuvaRing®
- Current breastfeeding or being within three months of parturition, at the time of screening.
- Evidence of clinically significant cardiac, respiratory, hepatic, gastrointestinal, endocrine, hematologic, psychiatric, neurologic, reproductive, or allergic disease that would compromise the ability of the participant to provide informed consent, or to complete study procedures or study requirements as determined by the principal investigator or designated associate. The clinical significance of any abnormality is to be evaluated in the context of the safety of the patient volunteer and the objectives of this study.
Study Plan
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nuvaring (only arm)
Nuvaring use for six months, with monthly pickup of rings and returning of used rings, and other behavioral/clinical assessments conducted during the visit on day 21 of the menstrual cycle.
|
contraceptive vaginal ring with ethinyl estradiol and etonogestrel
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participant-reported Acceptability
Time Frame: Six months of product use
|
Using computer assisted self-reported questionnaires and focus group discussions
|
Six months of product use
|
Biological (Objective) measures of Adherence
Time Frame: Six months of product use
|
Composite of salivary estradiol assays (instantaneous adherence) and remnant-drug assay of returned used vaginal rings (cumulative adherence over 21 days of use)
|
Six months of product use
|
Local Immunological effects of vaginally delivered hormonal contraception as measured by immunophenotyping
Time Frame: Six months of product use
|
Immunophenotyping analysis of cervicovaginal lavage collected at each day21 visit in a subset of participants, reported as total CD3, CD38 cell counts and proportions of CD4:CD8 cells
|
Six months of product use
|
Participant-reported Adherence
Time Frame: Six months of product use
|
Using computer assisted self-reported questionnaires and focus group discussions
|
Six months of product use
|
Microbiological effect of vaginally delivered hormonal contraception
Time Frame: Six months of product use
|
Standard Nugent score of cervicovaginal lavage smears.
|
Six months of product use
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Mumbi Makanga, MBChB, Kenya Medical Research Institute
- Study Chair: Beatrice Nyagol, MN, Kenya Medical Research Institute
- Principal Investigator: Eleanor McLellan-Lemal, PhD, US CDC
- Study Chair: Mitesh Desai, MD, MPH, US CDC
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDC-NCHHSTP-6518
- SSC Protocol # 2609 (Other Identifier: Kenya Medical Research Institute (FWA00002066))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hormonal Contraception
-
University Hospital, Strasbourg, FranceCompletedFemale Hormonal ContraceptionFrance
-
University Hospital TuebingenGerman Research Foundation; Uppsala UniversityEnrolling by invitation
-
International Research Training Group 2804German Research Foundation; Uppsala University; University Hospital TuebingenRecruiting
-
BayerCompletedHormonal Intrauterine ContraceptionSpain
-
Emory UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingHormonal ContraceptionUnited States
-
University Hospital TuebingenGerman Research Foundation; Uppsala UniversityNot yet recruiting
-
Mayo ClinicRecruitingHormonal Gender-Affirming TherapyUnited States
-
Charite University, Berlin, GermanyUnknownGlucose Metabolism | Satiety | Hormonal ChangesGermany
-
Western Galilee Hospital-NahariyaCompletedPrevious Cesarean Section | Induction of Labor | Hormonal ChangesIsrael
Clinical Trials on Nuvaring
-
Evestra Inc.RecruitingContraception | Female | Healthy WomenCanada
-
University Hospital, GhentFund for Scientific Research, Flanders, BelgiumCompleted
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID)CompletedBacterial VaginosisUnited States
-
Organon and CoCompletedContraception: Optional Applicator for Insertion of Vaginal Ring
-
Desmond Tutu HIV CentreUnknown
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV | Bacterial VaginosisKenya
-
Organon and CoCompleted
-
Oregon Health and Science UniversityOregon Clinical and Translational Research InstituteCompletedContraceptive Usage | Vaginal Epithelial DisruptionUnited States
-
University of SaskatchewanCanadian Institutes of Health Research (CIHR)Completed
-
Eastern Virginia Medical SchoolMerck Sharp & Dohme LLCUnknownVaginosis, BacterialUnited States